Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease
| Status: | Archived |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2009 |
| End Date: | February 2011 |
The purpose of this study is to examine the effects of the digibind drug on hemodialysis
patients with high blood pressure. Digibind is used to treat toxicity from digoxin and
digoxin-like molecules which may contribute to high blood pressure.
High blood pressure is a very common problem in patients with kidney disease. Researchers
have noted that there are certain molecules in the blood of these patients that may be
contributing to the high blood pressure. In particular these molecules have been labeled as
"digoxin-like substances." Digoxin is a drug made from a certain plant that may contribute
to high blood pressure. In research animals with kidney failure, it has been noted that the
use of Digibind helps to lower the blood pressure in these animals. Digibind is a drug made
from sheep that is used to treat the toxicity from digoxin as well as toxicity from
molecules similar to digoxin.
In this study, volunteers that are on hemodialysis and have high blood pressure will be
given a placebo or the digibind drug intravenously on two separate visits. The volunteers
will then wear a 24-hour blood pressure monitor and return the following day. Volunteers
will receive the Digibind at one visit during the study, and the placebo on the other visit.
We found this trial at
1
site
Click here to add this to my saved trials
